top of page
PleoPharma, Inc.
Feb 13
FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC's INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER:
A POTENTIAL FIRST IN TREATMENT Fast Track Designation highlights the potential of PP-01 to address a serious and unmet need for patients...
PleoPharma, Inc.
Nov 18, 2024
PLEOPHARMA, INC. Presents Positive Cannabis Withdrawal Clinical Trial Results at AAAP Annual Meeting
PHOENIXVILLE, Pa., Nov. 18, 2024 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on cannabis-related health issues
PleoPharma, Inc.
Oct 7, 2024
PLEOPHARMA, INC. Strengthens Patent Portfolio with Issuance of Two U.S. Patents
PHOENIXVILLE, Pa., Oct. 7, 2024 PleoPharma, Inc., a privately held company focused on Cannabis-related health issues, announced today that
PleoPharma, Inc.
Sep 19, 2024
PLEOPHARMA, INC. PARTICIPATES IN THE LIFE SCIENCES PA'S LIFE SCIENCE FUTURE CONFERENCE
PHOENIXVILLE, Pa., Sept. 19, 2024 -- PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today..
PleoPharma, Inc.
Sep 5, 2024
PLEOPHARMA, INC. REPORTS POSITIVE PHASE 2b CLINICAL TRIAL DATA FOR MITIGATION OF CANNABIS WITHDRAWAL: A POTENTIAL FIRST IN CLASS TREATMENT
PHOENIXVILLE, Pa., Sept. 5, 2024Â --Â PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today...
PleoPharma, Inc.
Jun 30, 2023
PleoPharma Inc. Completed a $17.5 Million Series A Financing Funding a Phase 2b Study for Cannabis Addiction and Withdrawal
June 2023 - PleoPharma Inc, announces it completed a Series A financing of $17.5 Million led by DynaGrow Capital, MintPharma Capital and...
bottom of page